SMMT (STOCKS)
Summit Therapeutics Inc. Common Stock
$13.407000
-0.593000 (-4.24%)
Prev close: $14.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Robert William Duggan; Mahkam Zanganeh, DDS, MBA
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $10,564.36M
- Employees
- 159
- P/E (TTM)
- -11.93
- P/B (TTM)
- 19.01
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
11
Buy
6
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.28 | $-0.28 | +0.0049 | +1.72% |
|
Mar 2026 (Q1)
|
$-0.24 | $-0.18 | -0.0599 | -33.26% |
|
Dec 2025 (Q4)
|
$-0.29 | $-0.07 | -0.2244 | -342.07% |
|
Sep 2025 (Q3)
|
$-0.31 | $-0.13 | -0.1755 | -130.48% |
Financial Statements
| Nonoperating Income/Loss | $18.76M |
| Operating Expenses | $874.84M |
| Income/Loss From Continuing Operations After Tax | -$856.09M |
| Income/Loss From Continuing Operations Before Tax | -$856.09M |
| Net Income/Loss | -$856.09M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$856.09M |
| Net Income/Loss Available To Common Stockholders, Basic | -$856.09M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.11 |
| Diluted Earnings Per Share | -$1.11 |
| Basic Average Shares | 1,526,554,458 |
| Diluted Average Shares | 1,526,554,458 |
| Assets | $752.19M |
| Current Assets | $720.58M |
| Noncurrent Assets | $31.61M |
| Fixed Assets | $1.78M |
| Other Non-current Assets | $29.83M |
| Liabilities | $122.20M |
| Current Liabilities | $103.57M |
| Accounts Payable | $22.90M |
| Wages | $9.44M |
| Other Current Liabilities | $71.23M |
| Noncurrent Liabilities | $18.64M |
| Equity | $629.98M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $629.98M |
| Liabilities And Equity | $752.19M |
| Net Cash Flow From Operating Activities | -$458.43M |
| Net Cash Flow From Operating Activities, Continuing | -$458.43M |
| Net Cash Flow From Investing Activities | -$262.57M |
| Net Cash Flow From Investing Activities, Continuing | -$262.57M |
| Net Cash Flow From Financing Activities | $842.51M |
| Net Cash Flow From Financing Activities, Continuing | $842.51M |
| Net Cash Flow | $121.51M |
| Net Cash Flow, Continuing | $121.51M |
| Comprehensive Income/Loss | -$856.00M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$856.00M |
| Other Comprehensive Income/Loss | -$856.00M |
| Other Comprehensive Income/Loss Attributable To Parent | $87.00K |